Stone medicine breakthrough! Take 11 new products 32 varieties have been evaluated.

On September 4th, Shipharma Group released its interim results report, which said that in 2020 H1 achieved revenue of RMB12.59 billion, up 12.6% YoY;
At present, stone medicine has 32 varieties (13 first evaluation), 8 varieties into the third batch of harvesting and all the winning bid;
results exceeded expectations, with 11 varieties from 2020 to August 27, Shi Pharmaceutical Group releasing its interim results report, with operating income of RMB12.59 billion in the first half of 2020, up 12.6% YoY, and net profit of RMB2.31 billion, up 23.2% YoY.
revenue and net profit both increased, and the results exceeded market expectations.
revenue of the pharmaceutical business, which consists of innovative drugs and general medicines, exceeded 10 billion yuan, up 16.7% YoY.
Among them, the anti-tumor product line grew strongly and became an important growth point, achieving revenue of 3.131 billion yuan in the first half of 2020, up 44.4% YoY;
Group vigorously promoted research and development innovation, in the first half of 2020 research and development costs reached 1.45 billion yuan, an increase of 54.2% YoY, accounting for 14.2% of the pharmaceutical revenue, in the industry-leading level.
meters intranet data show that in terms of status start time, so far in 2020 Stone Pharmaceutical Group has 11 new products approved for listing.
Table 1:2020 to date Stone Pharmaceutical Group approved for listing of varieties Note: with the first review of the varieties of 11 newly approved varieties have 10 new registered classification of production, approved after production as passed a consistent evaluation.
3 varieties of cider acid schonithini capsules, hydrochloric acid praxso tablets, injection boron zomi for the first review, of which hydrochloric acid prakso tablets, injection borate zomi for exclusive review.
32 varieties over-evaluation, 7 "barefoot" varieties to be released scale 2: Stone Pharmaceutical Group has been evaluated varieties of Minetrap data show that the current Stone Pharmaceutical Group a total of 32 varieties through or as if through consistency evaluation, of which 1 3 for the first review, Gremethyr dispersion tablets, hydrochloric acid renitin capsules, injection boron tyzomi, cephalosporine tablets, hydrochloric acid Prakso tablets, hydrochloric acid quemado tablets 6 varieties exclusive review.
From the evaluation time (status update date), in 2020 Stone Pharmaceutical Group will usher in the peak evaluation, so far 14 varieties have been evaluated (excluding new specifications), more than last year's full-year reviews (12 varieties over-reviewed).
stone drug evaluation varieties, cephalosporine, Monrust, Inapri, clopidogrel, imatini for 4 plus 7 sets of varieties, when the stone medicine because of the failure to participate in the bidding, and now successfully obtained admission "tickets"; Gremethal for the second batch of varieties, stone medicine to participate in 5 varieties of bidding, yew alcohol (albumin binding type), amosiline, azithromycin 3 varieties successfully winning the bid;
Table 3: Stone Pharmaceutical Group's third batch of winning bids in the case of 8 winning varieties, Meigang, Selesibu, Menglust chewing tablets, ibuprofen particles and other varieties, stone medicine supply of more provinces and regions, Jiangsu, Hebei, Beijing and other provinces and regions for the key selection of stone medicine.
In the end-of-term competition pattern of China's public medical institutions in 2019, the market share of stone drugs in methonone oral regular release agent type, metformin oral regular release dosage form, metformin slow release control agent type, tegrelo oral regular release dosage form, Celexib oral regular release dosage form, Mengrust chewing tablets, Katopuri oral regular release agent type 7 varieties has a lower market share or 0, and the market is expected to develop rapidly.
49 conformity evaluation varieties are under review, 8 varieties to grab the first imitation table 4: Stone Pharmaceutical Group consistency evaluation in the review situation (including new classification of production) At present, Stone Pharmaceutical Group has 78 varieties submitted a conformity evaluation supplementary application or new classification of production (excluding imitation 6 categories by new classification review), of which 28 Varieties through or as if through consistency evaluation, 1 variety is not approved, 21 of the 49 varieties under review have not yet been evaluated by enterprises, 49 varieties cover 8 major therapeutic areas, of which the highest proportion of systemic anti-infectant drugs, up to 30.6%, followed by neurological drugs, accounting for 16.3%.
Table 5: 8 of the 49 varieties not listed with generic drugs have not yet been approved for listing.
In addition to shakuba quartzan sodium tablets, the remaining 7 varieties were first reported by Stone Pharmaceutical Group in a new classification, of which 6 varieties of B cholesterol sulfate compounds injected with bisphenycin B cholesterol, icingaf softgels of ethyl sulfonate, icinga tablets, ipanlione tablets, Ilitacon lipid injections, and candishatan ammonia tablets were exclusively reported.
Gendermycin B is a polyene antifungal antibiotic, the domestic product has not yet been approved compound products, stone medicine exclusively reported and "clinically urgently needed, market shortage of drug registration application" into the priority review; Crater is the world's first gland ganache A2A-subject antagonist, which can be used in concert with drugs containing L-Doba to improve end-of-dose performance in Parkinson's patients, and the original product has not yet entered the domestic market;
sources: MED2.0 China Drug Review Database, China's public medical institutions terminal competition pattern, etc. Note: data statistics as of September 3, if there are omissions, welcome to point out!